Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

Terence M. Williams, MD, PhD, discussed the phase 1 DINOMITE trial of radiation therapy and papaverine in rectal cancer at ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Among patients with chronic hypoparathyroidism, palopegteriparatide improved skeletal dynamics and renal function at 2 years, according to new data from the PaTHway trial. As Healio previously ...

Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and ...

Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers Cancer Institute, anticipates groundbreaking data at the American Society of Clinical ...

A groundbreaking new drug called zilebesiran has shown that just one injection every six months, when added to standard pills, can significantly lower blood pressure by 4 to 12 points depending on the ...

An updated framework for addressing traumatic brain injury places the focus on the acute phase, while considering internal, external and modifying factors that influence outcomes from these events, ...

Rocket Pharmaceuticals shares plummeted 60% Tuesday after the firm said it halted a study of a gene-therapy drug for Danon ...